Prot #KZR‐616‐208: A Randomized, Double‐blind, Placebo‐controlled, Phase 2a Study with Open‐label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR‐616) in Patients with Autoimmune Hepatitis

Project: Research project

Project Details

StatusActive
Effective start/end date7/18/237/18/26

Funding

  • Kezar Life Sciences, Inc. (Prot #KZR-616-208)